Back to results
US 2014/0228240 A1Published application
Screening Blood for Protein Biomarkers and Uses Thereof in Alzheimer's Disease and Mild Cognitive Impairment
AssigneeEmory University
InventorWilliam Hu
Life of this patent
Estimating the term…
Abstract
This disclosure is in the area of medical diagnostics that provides a method to assist in diagnosis and monitoring the progression of Alzheimer's disease and mild cognitive impairment (MCI).
Claims44
A method of determining if a subject has Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI) or is at risk of developing AD or MCI comprising
- (a) measuring the protein levels of Apolipoprotein E (apoE);
- B-type natriuretic peptide;
- C-reactive protein;
- and pancreatic polypeptide in a blood sample from the subject
- (b) optionally measuring the protein level Cortisol, FAS, IL-3, IL-10, IL-12p40, IL-13, IL-15, Osteopontin, Resistin, Stem cell factor, E-selectin, serum amyloid protein, or any combination thereof in the blood sample from the subject;
- and
- (c) determining that the subject has Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), or is at risk of developing AD or MCI when one or more of the following first conditions:
- (i) the level of apoE in the subject's blood sample is reduced relative to an apoE control value;
- (ii) the level of B-type natriuretic peptide in the subject's blood sample is increased relative to a B-type natriuretic peptide control value;
- (iii) the level of C-reactive protein in the subject's blood sample is reduced relative to a C-reactive protein control value;
- (iv) the level of pancreatic polypeptide in the subject's blood sample is increased relative to a pancreatic polypeptide control value;
- and optionally one or more of the second conditions:
- (i) the level of Cortisol in the subject's blood sample is increased relative to a Cortisol control value;
- (ii) the level of FAS in the subject's blood sample is increased relative to a FAS control value;
- (iii) the level of IL-3 protein in the subject's blood sample is increased relative to an IL-3 control value;
- (iv) the level of IL-10 in the subject's blood sample is increased relative to an IL-10 control value;
- (v) the level of IL-12p40 in the subject's blood sample is increased relative to an IL-12p40 control value;
- (vi) the level of IL-13 in the subject's blood sample is increased relative to an IL-13 control value;
- (vii) the level of IL-15 in the subject's blood sample is increased relative to an IL-15 control value;
- (viii) the level of Osteopontin in the subject's blood sample is increased relative to an Osteopontin control value;
- (ix) the level of Resistin in the subject's blood sample is increased relative to a Resistin control value;
- (x) the level of Stem cell factor in the subject's blood sample is increased relative to a Stem cell factor control value;
- (xi) the level of E-selectin in the subject's blood sample is reduced relative to an E-selectin control value;
- (xii) the level of serum amyloid protein in the subject's blood sample is reduced relative to a serum amyloid protein control value are met.
21 more elements
The method of 14 wherein the immunoassay is bead-based assay.
A method of determining the efficacy of a treatment for AD or MCI comprising
- (a) measuring the protein levels of Apolipoprotein E (apoE);
- B-type natriuretic peptide;
- C-reactive protein;
- and pancreatic polypeptide in a second blood sample from a subject with AD or MCI undergoing a treatment for AD or MCI, wherein the second blood sample is obtained from the subject after a sufficient amount of time has passed for the treatment to reduce one or more symptoms of the AD or MCI;
- (b) optionally measuring the protein level of Cortisol, FAS, IL-3, IL-10, IL-12p40, IL-13, IL-15, Osteopontin, Resistin, Stem cell factor, E-selectin, serum amyloid protein, or any combination thereof in the second blood sample from the subject;
- (c) determining that the treatment is effective for treating AD or MCI when one or more of the following first conditions:
- (i) the level of apoE in the subject's second blood sample is increased relative to a first blood sample taken from the subject prior the treatment;
- (ii) the level of B-type natriuretic peptide in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (iii) the level of C-reactive protein in the subject's second blood sample is increased relative to a first blood sample taken from the subject prior the treatment;
- (iv) the level of pancreatic polypeptide in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- and optionally one or more of the second conditions:
- (i) the level of Cortisol in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (ii) the level of FAS in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (iii) the level of IL-3 protein in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (iv) the level of IL-10 in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (v) the level of IL-12p40 in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (vi) the level of IL-13 in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (vii) the level of IL-15 in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (viii) the level of Osteopontin in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (ix) the level of Resistin in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (x) the level of Stem cell factor in the subject's second blood sample is decreased relative to a first blood sample taken from the subject prior the treatment;
- (xi) the level of E-selectin in the subject's second blood sample is increased relative to a first blood sample taken from the subject prior the treatment;
- (xii) the level of serum amyloid protein in the subject's second blood sample is increased relative to a first blood sample taken from the subject prior the treatment are met.
20 more elements
A method comprising the steps of,
- a) measuring a blood sample from a subject for levels of the following proteins Apolipoprotein E (apoE);
- B-type natriuretic peptide;
- C-reactive protein;
- and pancreatic polypeptide providing measured levels;
- b) comparing the normalized measured levels of proteins with reference levels wherein the reference levels are obtained from normalized measured values;
- c) determining whether the subject is at increased risk of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI);
- wherein if the subject has altered levels of the proteins compared to reference levels this indicates an increased risk of Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).
4 more elements
Dependencies are inferred from the claim text.